首页> 外文期刊>British Journal of Haematology >Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
【24h】

Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

机译:儿童多系统朗格汉斯细胞组织细胞增生症诊断时缺乏骨病变与预后不良有关

获取原文
获取原文并翻译 | 示例
           

摘要

Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO-) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin <100g/l, and/or white blood cell count <40x10(9)/l and/or platelet count <100x10(9)/l), spleen (>2cm below the costal margin), liver (>3cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 +/- 3% (n=230, 56 events) was reduced to 62 +/- 4% (n=156, 55 events) if this was absent (P=0007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 +/- 5% survival (n=105; 52 events) if patients had bony lesions, versus 47 +/- 5% (n=111; 39 events) if they did not (P=0014). This difference was retained in multivariate analysis (P=0048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH.
机译:骨骼受累通常是但不是普遍的朗格汉斯细胞组织细胞增生症(LCH)的特征。我们调查了诊断时骨病变的存在是否是LCH生存的预后因素。在诊断时评估了938位多系统(MS)LCH儿童的高(386 RO +)和低(RO-)风险。风险器官(RO +)的定义为:造血系统(血红蛋白<100g / l,和/或白细胞计数<40x10(9)/ l,和/或血小板计数<100x10(9)/ l),脾脏(>肋缘以下2厘米),肝脏(> 3厘米和/或低蛋白血症,低白蛋白血症,高胆红素血症和/或天冬氨酸转氨酶/丙氨酸转氨酶升高)。鉴于人们普遍认为LCH的预后随着疾病程度的增加而恶化,令人惊讶的发现是,在MS + RO + LCH中,骨受累生存的可能性降低了74 +/- 3%(n = 230,56个事件)如果不存在+/- 4%(n = 156,55个事件)(P = 0007)。在患有肝和造血或脾脏受累的患者亚组中观察到更大的差异:如果患者有骨性病变,则存活率为61 +/- 5%(n = 105; 52事件),而患者为47 +/- 5%( n = 111; 39个事件)(如果没有)(P = 0014)。这种差异保留在多变量分析中(P = 0048)。尽管尚无法解释,但我们得出的结论是,诊断时骨骼受累是MS + RO + LCH中先前无法识别的有利预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号